High prevalence of cholestasis, with increased conjugated bile acids in inflammatory bowel diseases patients

doi:10.12998/wjcc.v6.i4.44

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 4

This Article

(381)

(410)

(0)

(20)

(2)

(7149)

(11)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Cohort Study

World J Clin Cases. Apr 16, 2018; 6(4): 44-53
Published online Apr 16, 2018. doi: 10.12998/wjcc.v6.i4.44

Table 4 Bile acids subtypes

	TBA > 8 (80)	TBA < 8 (80)	P value
TBA	14.64 (1.24)	3.31 (0.22)	1.07 × 10^-15
Primary
CA	1.09 (0.29)	0.29 (0.04)	0.008
Cholic acid	1.09 (0.29)	0.29 (0.04)	0.008
CDC chenodeoxycholate	2.06 (0.41)	0.68 (0.13)	0.002
Secondary
DC	1.35 (0.27)	0.28 (0.04)	0.000
deoxycholate	1.35 (0.27)	0.28 (0.04)	0.000
LCA	0.07 (0.01)	0.07 (0.01)	0.9
lithocholic acid	0.07 (0.01)	0.07 (0.01)	0.9
Tertiary
UDC	0.34 (0.05)	0.14 (0.03)	0.000
ursodeoxycholate	0.34 (0.05)	0.14 (0.03)	0.000
Primary conjugated
TC	0.37 (0.08)	0.04 (0.01)	0.000
taurocholate	0.37 (0.08)	0.04 (0.01)	0.000
GCA	1.78 (0.28)	0.38 (0.05)	1.83 × 10^-6
gylcocholate acid	1.78 (0.28)	0.38 (0.05)	1.83 × 10^-6
TCDC	0.74 (0.11)	0.18 (0.02)	1.58 × 10^-6
taurochenodeoxycholate	0.74 (0.11)	0.18 (0.02)	1.58 × 10^-6
GCDC	4.72 (0.33)	1.42 (0.12)	1.54 × 10^-16
glycochenodeoxycholate	4.72 (0.33)	1.42 (0.12)	1.54 × 10^-16
Secondary conjugated
GDC	1.01 (0.10)	0.30 (0.04)	1.38 × 10^-9
glycodeoxycholate	1.01 (0.10)	0.30 (0.04)	1.38 × 10^-9
TDC	0.20 (0.03)	0.05 (0.01)	8.78 × 10^-7
taurodeoxycholate	0.20 (0.03)	0.05 (0.01)	8.78 × 10^-7
TLC	0.04 (0.01)	0.01 (0.00)	8.46 × 10^-5
taurolithocholate	0.04 (0.01)	0.01 (0.00)	8.46 × 10^-5
GLC	0.09 (0.01)	0.09 (0.01)	0.646
glycolithocholate	0.09 (0.01)	0.09 (0.01)	0.646
Tertiary conjugated
TUDC	0.06 (0.01)	0.001 (0.00)	1.69 × 10^-8
tauroursodeoxycholate	0.06 (0.01)	0.001 (0.00)	1.69 × 10^-8
GUDC	0.84 (0.12)	0.19 (0.03)	4.58 × 10^-7
glycoursodeoxycholate	0.84 (0.12)	0.19 (0.03)	4.58 × 10^-7
Hydroxydes
DHCA	0.004 (0.002)	0.001 (0.001)	0.291
dihydroxycholestanoic acid	0.004 (0.002)	0.001 (0.001)	0.291
THCA	0.001 (0.001)	0.000 (0.000)	0.275
trihydroxycholestanoic acid	0.001 (0.001)	0.000 (0.000)	0.275
Ratio
Primary/secondary	3.48 (0.92)	4.42 (1.34)	0.566
Primary/TBA	0.23 (0.05)	0.31 (0.04)	0.211
Conjugated glycine/taurine
Primary	11.64 (1.18)	10.70 (0.89)	0.537
Secondary	6.40 (0.61)	5.15 (0.66)	0.209

Bile acids subtypes expressed in μmol/L with standard deviation under bracket, in 80 patients with a total bile acids level of more than 8 μmol/L compared with 80 patients with a total bile acids level of less than 8 μmol/L. TBA: Total bile acids; CA: Cholic acid; CDC: Chenodeoxycholate; DC: Deoxycholate; LCA: Lithocholic acid; UDC: Ursodeoxycholate; TC: Taurocholate; GCA: Gylcocholate acid; TCDC: Taurochenodeoxycholate; GCDC: Glycochenodeoxycholate; TDC: Taurodeoxycholate; GDC: Glycodeoxycholate; TLC: Taurolithocholate; GLC: Glycolithocholate; TUDC: Tauroursodeoxycholate; GUDC: Glycoursodeoxycholate; DHCA: Dihydroxycholestanoic acid; THCA: Trihydroxycholestanoic acid.

Full Size Table

Citation: Girardin M, Hadengue A, Frossard JL, the Swiss IBD Cohort Study Group. High prevalence of cholestasis, with increased conjugated bile acids in inflammatory bowel diseases patients. World J Clin Cases 2018; 6(4): 44-53
URL: https://www.wjgnet.com/2307-8960/full/v6/i4/44.htm
DOI: https://dx.doi.org/10.12998/wjcc.v6.i4.44

Girardin M, Hadengue A, Frossard JL, the Swiss IBD Cohort Study Group. High prevalence of cholestasis, with increased conjugated bile acids in inflammatory bowel diseases patients. World J Clin Cases 2018; 6(4): 44-53 [PMID: 29670889 DOI: 10.12998/wjcc.v6.i4.44]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.